Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: GlobeNewswire
Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged Treatment in Difficult-to-Treat Patient Population Strengthened Financial Position with the Completion of a Public Equity Offering Raising Approximately $33.7 Million in Net Proceeds Expects Four Clinical Data Readouts Across Pipeline in 2020 Including Topline Results from Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the third quarter ended September 30, 2019 and provided an overview of the company’s recent progress. “2020 is poised to be a transformational year for Ovid. We expect multiple clinical trial data readouts across our p
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 [Seeking Alpha]Seeking Alpha
- Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at Wedbush. They set an "outperform" rating and a $8.00 price target on the stock.MarketBeat
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
OVID
Earnings
- 3/8/24 - Miss
OVID
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- OVID's page on the SEC website